Cubist Pharmaceuticals | search
Click here to view Cubist Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in CashCubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.
- Merck Completes Tender Offer to Acquire Cubist - Merck.comMerck Completes Tender Offer to Acquire Cubist. Print. January 21, 2015 8:00 am ET. Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the. outstanding shares of common stock of Cubist Pharmaceuticals, Inc.
- Cubist Pharmaceuticals - WikipediaMerck & Co. Website. www.cubist.com. Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA . . [1] The company employed 638 people, mostly in Lexington, MA. [2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion). [3]
- Years after Cubist buyout, Merck scores a new Zerbaxa ... - Fierce PharmaMerck hasn’t exactly made a fortune on its $9.5 billion Cubist Pharmaceuticals buyout, but now, a next-generation antibiotic it acquired in that deal has a brand-new indication that could help...
- Merck & Co. to Acquire Cubist Pharmaceuticals for $9.5 BillionMerck & Co. has agreed to acquire Cubist Pharmaceuticals, a biopharmaceutical company specializing in antibiotics, particularly for multidrug-resistant bacteria, for $9.5 billion. DCAT Value Chain Insights ( VCI ) examines the proposed acquisition for Merck’s portfolio and the renewed interest in the antibiotics market.
More
